Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 701–800 of 1,000
Cardiomyocyte GC1 Mediates Estrogenic Angiogenesis in Right Heart Remodeling
Fukuma, N., Tzimas, C., Russo, I., Dun, W., Lance, M. L., Zhang, Y., Kushner, J., Emala, C. W., Friebe, A., Tucker, N. R., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.326070 · Cited by 4
Balakumar, P., Mulukuri, N. V. L. S., & Jagadeesh, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108945 · Cited by 7
PhenoFit: a framework for determining computable phenotyping algorithm fitness for purpose and reuse
Wiley, L. K., Rasmussen, L. V., Levinson, R. T., Malinowski, J. R., Manemann, S. M., Wilson, M. P., Chapman, M., Pacheco, J. A., Walunas, T. L., Starren, J. B., et al. (2025) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaf195 · Cited by 7
Soluble guanylate cyclase modulators—a novel therapeutic approach for diabetic kidney disease
Xu, Y., Wu, X., Ge, M., Liang, K., Xing, J., Zhang, P., Huilin, L. I., Guo, Z., & Mei, X. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2595385 · Cited by 4
“…function in patients with worsening heart failure and reduced ejection fraction was similar to that of the placebo group, without demonstrating significant renal benefits [52,62]. although evidence of renal protection is lacking, its cardiovascular benefits may indirectly slow eGfr decline [63].”
Activating PRKG1 Variant Enhances Smooth Muscle Cell Deformability to Cause Aortopathy
Jost, M., Schweizer, M., Henning, P., Gorzelanny, C., Lehners, M., Ellinger, B., Boix-Campos, J., Kux, J.-M., Singh, S., Fachinger, A., et al. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101452 · Cited by 4
Pulmonary Hypertension Associated With Left Heart Disease
Khan, M. S., Borlaug, B. A., Butler, J., Gomberg‐Maitland, M., Humbert, M. J. C., Lam, C. S. P., Reddy, Y., Stone, G. W., Zannad, F. M., & Tedford, R. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.024 · Cited by 8
Self-citationHeart failure evidence update 2026
Liori, S., Kapelios, C. J., Savarese, G., & Filippatos, G. S. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10609-3 · Cited by 10
“The VICTORIA trial had established vericiguat, a soluble guanylate cyclase (sGC) stimulator, in patients with worsening HFrEF, demonstrating a 10% reduction in the composite of CV death or first HF hospitalization (HR 0.90, 95% CI 0.82–0.98, p = 0.02) [ 48 ].”
InfluentialPCPE-1 promotes cardiac fibrosis with aging and obesity
Hsiao, Y., Yoshida, Y., Tsuchimochi, H., Tang, J., Aung, T. M., Chang, C.-H., Barinda, A. J., Li, Z., Othman, N. S. B., Yoshizaki, T., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.195508 · Cited by 5
Quadruple therapy in heart failure: Why, when, and in whom?
PARASKEVAIDIS, I. A., Tsougos, E., & Kourek, C. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103352 · Cited by 5
Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials
van der Bijl, M. F., Scholte, N. T. B., van Oortmerssen, J. A. E., van Lennep, J. E. R., Schut, A., Westendorp, I. C. D., van der Boon, R. M. A., Brugts, J. J., Kardys, I., Appelman, Y., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag311 · Cited by 7
Free fatty acid receptor 4 in cardiac myocytes ameliorates ischaemic cardiomyopathy
Zhang, M. J., Puccini, S. J., Karachenets, S., Gyberg, D. J., Pakkiriswami, S., Sumera, M. K., Gemilere, R., Weir, N. L., Torres, S. L., Healy, C. L., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag175 · Cited by 4
Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure
Cao, Y., Sun, Y., Miao, B., Zhang, X., Zhao, Q., Qi, L., Chen, Y., & Zhu, L. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00664-y · Cited by 6
Kittipibul, V., Mentz, R. J., Young, R., Butler, J., Ezekowitz, J. A., Lam, C. S. P., Ponikowski, P. P., Voors, A. A., Corda, S., McMullan, C. J., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15134 · Cited by 4
Self-citationHlaváček, D., Haluzík, M., Mahrík, J., Popivnyak, G., Kasperová, B. J., & Ivák, P. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2511388 · Cited by 4
“New treatment options are still warranted, especially in patients with HFrEF progression, despite GDMT optimization [ 42].”
Derisking Phase II Clinical Trials in Heart Failure
Mann, D. L., Felker, G. M., Unger, E. F., Wittes, J. T., Bozkurt, B., Malik, F. I., Stockbridge, N., Saville, B. R., Fiuzat, M., O’Connor, C. M., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.003 · Cited by 5
Self-citationBreaking new ground in heart failure management: novel therapies and future frontiers
Khalid, A., Rodriguez, P., Tasouli-Drakou, V., Ahmed, A.-B., Thatcher, S., Dugal, J. K., & Singh, A. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1643971 · Cited by 8
Characterizing real-world use of vericiguat in the United States
Victores, A., Bash, L. D., Ru, B., Marks‐Anglin, A., McMullan, C. J., Stevenson, A. S., Obi, E. N., Mentz, R. J., & Januzzi, J. L. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.021 · Cited by 4
The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice
Tricarico, L., Correale, M., Bevere, E. M. L., Brunetti, N. D., & Iacoviello, M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39886 · Cited by 4
“…(Soluble guanylate Cyclase stimulatoR in heArTfailurE Study) [ 24,25] and VICTORIA (vericiguat in patients with Heart Failure and Reduced Ejection Fraction) [26] trials have been the primary studies assessing the efficacy, safety and tolerability of vericiguat in patients with HFrEF (Table 1, Ref.”
InfluentialMeems, L. M. G., van Veldhuisen, D. J., & de Boer, R. A. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01453-7 · Cited by 5
Жиров, И. В., Safronova, N. V., & Tereshchenko, S. N. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4949 · Cited by 4
Efficacy of three novel drugs in the treatment of heart failure: A network meta-analysis
Luo, L., Xu, Y., Tang, K., Wu, J., Li, D., Ran, J., Zhang, L., Wang, D., Zhao, D., Yu, M., et al. (2022) · Medicine · doi:10.1097/md.0000000000029415 · Cited by 5
Frühe Implementierung der „Fantastic four“ bei Herzinsuffizienz mit reduzierter Ejektionsfraktion
Soltani, S., Böhm, M., Frey, N., Eden, M., Abdin, A., & Bauersachs, J. K. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1760-3843 · Cited by 4
Novel Drugs Approved in 2021-2022
Do, M., Shin, B., Lioudis, E., & Munn, E. (2022) · Transformative Medicine · doi:10.54299/tmed/zcno1399 · Cited by 4
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender
Iacoviello, M., Pugliese, R., Correale, M., & Brunetti, N. D. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00583-w · Cited by 5
Soluble Guanylate Cyclase β1 Subunit Represses Human Glioblastoma Growth
Xiao, H., Zhu, H., Bögler, O., Mónica, F. Z., Kots, A. Y., Murad, F., & Bian, K. (2023) · Cancers · doi:10.3390/cancers15051567 · Cited by 4
“These sGC stimulators enhance sGC activity independently from NO [10,11].”
BackgroundCharacteristics and Trends in Clinical Trials of Cardiovascular Drugs in China from 2009 to 2021
Hao, J., Li, C., Li, J., Wang, C., Li, Y., He, C., Liu, W., Li, S., Zuo, L., & Wen, H. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00575-8 · Cited by 4
Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
Felker, G. M., North, R., Mulder, H. S., Jones, W. S., Anstrom, K. J., Patel, M. J., Butler, J., Ezekowitz, J. A., Lam, C. S. P., O’Connor, C. M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.04.015 · Cited by 4
Self-citationThe prediction model of the short-term outcome in elderly heart failure patients
Cao, M., Ju, Y., Yang, D., Jin, H., Zhang, K., & Leng, J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10323-4 · Cited by 4
Horibe, H., Ando, K., Maekawa, Y., Narisawa, M., Yamase, Y., Funabiki, J., Ueyama, C., Takemoto, Y., Shigeta, T., Hibino, T., et al. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.08.008 · Cited by 4
Defining a Path Toward Improved Heart Failure Care
Desai, N. R., & Clark, K. A. A. (2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89418 · Cited by 4
Das, B. B. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00585-8 · Cited by 4
“Vericiguat, an sGC stimulator that restores the NO-sGC-cGMP pathway by stimulating sGC levels and enhancing endogenous NO sensitivity, is helpful in HF [87].”
BackgroundThe Evolving Role of Vericiguat in Patients With Chronic Heart Failure
Dies, R., Jackson, C. N., Flanagan, C. J., Sinnathamby, E. S., Spillers, N. J., Potharaju, P., Singh, N., Varrassi, G., Ahmadzadeh, S., Shekoohi, S., et al. (2023) · Cureus · doi:10.7759/cureus.49782 · Cited by 6
“This clinical trial showed that among patients with HFrEF, the incidence of death or hospitalization among patients taking vericiguat was lower than that of those who received a placebo [66].”
BackgroundAbuelazm, M. T., Attia, A. M., Abdelnabi, M., Jafar, U., Almaadawy, O., Elzeftawy, M. A., Mahmoud, A., Albakri, K. A., & Abdelazeem, B. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00437-x · Cited by 4
Pharmacological Treatment of Heart Failure: Recent Advances
Chan, J. C. H., & Siddiqui, A. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x270178231228061314 · Cited by 6
“The VICTORIA trial randomly assigned 5050 patients with HFrEF to vericiguat (10 mg daily) or placebo [31].”
InfluentialTromp, J., Lam, C. S. P., Alemayehu, W. G., de Filippi, C. R., Melenovský, V., Sliwa, K. S., Lopatin, Y. M., Arango, J. L., Bahit, M. C., Roessig, L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3397 · Cited by 6
Self-citationKinoshita, H., Sugino, H., Fujita, K., Sumimoto, Y., Masada, K., Shimonaga, T., Suga, A., Toko, M., Taniyasu, K., Ushirozako, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13175264 · Cited by 3
“The VICTORIA trial demonstrated the effects of Vericiguat therapy to reduce cardiovascular mortality and heart failure hospitalisations compared with placebo in patients with heart failure with reduced ejection fraction (HFrEF) who were at high risk for worsening heart failure [14,15].”
BackgroundInfluentialPediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy
Koubský, K. (2024) · Physiological Research · doi:10.33549/physiolres.935438 · Cited by 10
“Benefits have been demonstrated in symptomatic adults with HF with reduced ejection fraction [91].”
Management of Pediatric Heart Failure
Dipchand, A. I. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2024.0320 · Cited by 6
Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction
Taqanaki, P. B., Aromolaran, K. A., & Aromolaran, A. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413423 · Cited by 7
Prediction and Longer-Term Outcomes of All-cause and Cardiovascular Mortality in the HEART-FID Trial
Ezekowitz, J. A., Mulder, H. S., Mentz, R. J., Butler, J., Pasquale, C. G. D., Lewis, G. D., O’Meara, E., Ponikowski, P. P., Troughton, R. W., Wong, Y. W., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.01.009 · Cited by 4
Self-citationHüttl, M., Miklovič, M., Gawryś, O., Molnár, M., Škaroupková, P., Vaňourková, Z., Kikerlová, S., Malínská, H., Kala, P., Honetschlägerová, Z., et al. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004009 · Cited by 4
Filling the gaps in guideline-directed care
Betz, C. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88672 · Cited by 5
Weber, R. E., Schulze, K. M., Colburn, T. D., Horn, A. G., Hageman, K. S., Ade, C. J., Hall, S. E., Sandner, P., Musch, T. I., & Poole, D. C. (2021) · Nitric Oxide · doi:10.1016/j.niox.2021.12.001 · Cited by 4
Batchelor, R., Tie, E. N., Romero, L., Hopper, I., & Kaye, D. M. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.11.001 · Cited by 7
Yu, X., Yan, H., Zhu, Z., Zhang, W., Liu, B., Ma, M., Zhang, X., Wei, N., Wang, J., & Liu, F. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01253-y · Cited by 4
“The starting age for the base case was 67 years, consistent with the mean age in the VICTORIA study (Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction) [21], and the simulation is lifetime long (360 cycles, equal to 30 years).”
MethodInfluentialLuo, H., Gao, L., Long, H., Zhou, Z., Xu, S., Li, F., Li, H., Cheng, Y., Li, C., Peng, X.-Y., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03484-6 · Cited by 4
“Patients considered ‘responder’ met any of the following characteristics: (1) their clinical symptoms improved (choking sensation in chest, shortness of breath and palpitation) and (2) clear cardiac function indicators (NT-proBNP, LVEF, NYHA class and 6-min walking distance) improved after 3 to 6 months [29, 30].”
BackgroundPrognostic Role of Contraindicated Drugs in Hospitalized Patients with Decompensated Heart Failure
Parish, O., Cannata, A. N., Shamsi, A., Jordán‐Ríos, A., Albarjas, M., Piper, S. E., Scott, P. A., Bromage, D. I., & McDonagh, T. A. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001413 · Cited by 6
Pulmonary hypertension associated with left heart disease
Wißmüller, M., Dohr, J., Adler, J., Ochs, L., Tichelbäcker, T., Hohmann, C., Baldus, S. E., & Rosenkranz, S. (2023) · Herz · doi:10.1007/s00059-023-05189-z · Cited by 4
“This led to the phase III VICTORIA trial, which proved the efficacy of vericiguat as an add-on therapy in patients with HFrEF who had undergone cardiac decompensation [50].”
MethodYokoi, A., Kawada, T., Yokota, S., Kakuuchi, M., Matsushita, H., Nishiura, A., Li, M., Uemura, K., Alexander, J., Tanaka, R., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286767 · Cited by 4
“In the VICTORIA trial [11], which showed the clinical benefits of vericiguat in HFrEF (heart failure with reduced ejection fraction) patients, the BP reduction in the vericiguat group was very small, which is considered one of the advantages of vericiguat over other guideline-directed medical therapies.”
MethodHeart Failure Guideline Directed Medical Therapy: Which One and When?
Dimza, M., & Aranda, J. M. (2023) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2023.0077 · Cited by 4
Acute heart failure – an EFIM guideline critical appraisal and adaptation for internists
Kokorin, K. V. A., Franco, Á. G., Cittadini, A., Kalējs, O., Larina, V. N., Marra, A. M., Medrano, F. J., Monhart, Z., Morbidoni, L., Pimenta, J. M., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.02.028 · Cited by 6
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure
Mansoor, T., Khalid, S. N., Bilal, M. I., Ijaz, S. H., Fudim, M., Greene, S. J., Warraich, H. J., Nambi, V., Virani, S. S., Fonarow, G. C., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00658-0 · Cited by 4
“In high-risk HF patients, CV death and HF hospitalization were shown to be lower in patients receiving vericiguat compared to placebo [33, 34].”
Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction
Chaudhary, A., Alreefi, F., & Aziz, M. (2021) · CJC Open · doi:10.1016/j.cjco.2021.01.006 · Cited by 4
“This study provided the basis for the phase III VICTORIA trial, the largest trial to date in this class (N 1⁄4 5050), which examined the efficacy and safety of vericiguat 10 mg vs placebo in high-risk HF patients.(9) Patients with NYHA functional class II-IV HF and LVEF < 45% were included if they had a HF hospitaliza…”
BackgroundMethodVericiguat in the management of heart failure with reduced ejection fraction
Aziz, H., Gouda, P., & Sharma, A. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab022 · Cited by 4
Silva‐Cardoso, J., Fonseca, C., Franco, F., Morais, J., Ferreira, J., & Brito, D. A. (2021) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2021.11.017 · Cited by 4
Inpatient Initiation of Sacubitril/Valsartan
Chilbert, M. R., Rogers, K. C., Ciriello, D. N., Rovelli, R. J., & Woodruff, A. E. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020947446 · Cited by 4
Extra-Cardiac Targets in the Management of Cardiometabolic Disease: Device-Based Therapies
Jorbenadze, A., Fudim, M., Mahfoud, F., Adamson, P. B., Bekfani, T., Wachter, R., Sievert, H., Ponikowski, P. P., Cleland, J. G. F., & Anker, S. D. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13361 · Cited by 3
“Additional pathways mostly independent of neurohormonal modulation are the sodium glucose cotransport inhibitors(8) and soluble guanylate cyclase activators.(9) Pharma-”
BackgroundSelf-citationPaneni, F., Sciarretta, S., & Costantino, S. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa196 · Cited by 4
Phosphodiesterase-5 Inhibitors and Survival in Men With Coronary Artery Disease
Maas, R., & Rodionov, R. N. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.021 · Cited by 4
Are Left Ventricular Ejection Fraction Phenotypes Meaningful in Acute Heart Failure?
Baudry, G., Lescroart, M., & Kimmoun, A. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2889 · Cited by 4
Heart Failure Hospitalizations Versus Cardiovascular Mortality in Heart Failure Trials
Kaul, S., Siddiqi, T. J., Anker, S. D., & Butler, J. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.074 · Cited by 4
Self-citationThe efficacy of vericiguat for heart failure: A meta-analysis of randomized controlled trials
Ma, G., Pan, Y., Qu, C., & Li, F. (2023) · Medicine · doi:10.1097/md.0000000000033807 · Cited by 5
“Three hundred sixty-five publications were searched after the initial search of databases, and 4 RCTs were ultimately included in the meta-analysis.[9,12,15,21] Table 1 demonstrated the baseline characteristics of 4 eligible RCTs.”
BackgroundMethodResultInfluentialWesterhout, C. M., Rathwell, S., Anstrom, K. J., Hernandez, A. F., Ponikowski, P. P., Ezekowitz, J. A., Voors, A. A., Felker, G. M., Bakal, J. A., Blaustein, R. O., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.038 · Cited by 5
Self-citationVericiguat as a novel PPARα ligand alleviates pressure-overload-induced heart failure
Zhang, P., Yuan, C., Zhan, Z., Zhou, J., Huang, P., Wang, W., Qian, J., & Shan, P. (2025) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2025.117473 · Cited by 6
Vericiguat across the heart failure spectrum
Kohsaka, S., & Heidenreich, P. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01765-9 · Cited by 3
Geavlete, O. D., Ambrosy, A. P., Skowronski, J. N., Abdelhamid, M., Girerd, N., Alexy, T., Chioncel, O. D., & Monzo, L. (2026) · Heart Failure Reviews · doi:10.1007/s10741-025-10593-0 · Cited by 5
“A total of death or HF hospitalization) compared with contemporary drugs, such as SGLT2i (DAPA-HF: ARR 4.0, NNT/year 25; EMPEROR-Reduced, ARR 5.2, NNT/year 19) [ 33, 34], and vericiguat (VICTORIA trial, ARR 4.2, NNT/year 24) [38] (Fig.”
InfluentialDatta, S., Majumder, S., Gulsin, G. S., Banerjee, A., Primus, C., Mohammed, S., Ricci, F., Aung, N., Sen, G., Gallagher, A. M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag029 · Cited by 4
“35 Additionally, they do not have any blood pressure lowering effects.”
Atrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates
Kantharia, B. K., Wu, L., Hulsurkar, M. M., Karimzad, K., Shah, A. N., Narasimhan, B., Wehrens, X. H. T., Linz, D., & Heijman, J. (2026) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2025.53 · Cited by 3
“53,100,101 Modulating cell senescence might provide a basis for novel therapeutic approaches to AF.”
Armentaro, G., Scarcelli, M. R., Severini, G., Pastura, C. A., Cassano, V., Maruca, F., Marincola, L. F., Cortese, G., Condoleo, V., Miceli, S., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030466 · Cited by 4
“In the VICTORIA trial, vericiguat showed a 10% relative risk reduction in the composite endpoint of cardiovascular death or first HF hospitalization (HR 0.90; 95% CI 0.82–0.98; p = 0.02), with an NNT of 24 patients, to prevent one event in one year [29].”
InfluentialThe NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial
Solomon, S. D., McMurray, J. J. V., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Voors, A. A., Claggett, B. L., Nuehrenberg, T. G., Rizkala, A. R., Koch, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04313-w · Cited by 3
“The soluble (cytosolic) guanylate cyclase stimulator vericiguat has shown modest success in HF 15,16 , and additional approaches targeting this pathway, including the prevention of cGMP breakdown with PDE9 inhibition, are in development 17 .”
Self-citationCardiac contractility modulation in heart failure with reduced ejection fraction treatment
Chugunov, I. A., Mareev, Y. V., Fudim, M., Миронова, Н. А., VIu, M., & Davtyan, K. V. (2022) · Kardiologiia · doi:10.18087/cardio.2022.11.n2014 · Cited by 3
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction
Lanfear, D. E., Njoroge, J. N., Adams, K. F., Anand, I. S., Fang, J. C.-T., Ramires, F. J. A., Sliwa, K. S., Badat, A., Burgess, L. J., Gorodeski, E. Z., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.021 · Cited by 3
Yang, S., Zhao, Y., Cheng, X., Zhan, T., Tian, J., Liu, X., Ma, C., Wang, Z., Jin, L.-Y., Liu, Q., et al. (2023) · Engineering · doi:10.1016/j.eng.2023.06.009 · Cited by 3
Medical Therapy of Heart Failure with Reduced Ejection Fraction—A Call for Comparative Research
Cotter, G., Davison, B. A., Mebazaa, A., Takagi, K., Novosadova, M., Freund, Y., & Solal, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091803 · Cited by 3
“Finally, recently, the Victoria study has been published [7], examining the effects of bericinguat in patients with HFREF and a recent HF exacerbation.”
BackgroundNguyen, L., & Baker, D. E. (2021) · Hospital Pharmacy · doi:10.1177/00185787211016338 · Cited by 3
Worsening heart failure in Colombia: Analysis from RECOLFACA registry
Saldarriaga, C., Gómez‐Mesa, J. E., Rivera-Toquica, A. A., Gómez, P. R., Toquica, F. E. R., Guardiola, G. T., Espitia, M. D. L., Castro-Osorio, E. E., Asprilla, C. A. R., Garzón, N. A. L., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101301 · Cited by 3
Quintana, A. G., Mayoral, A. R., Cepeda-Rodrigo, J. M., Zamorano, J. L., & González‐Juanatey, J. R. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00002-4 · Cited by 3
Jia, X., Liu, Y., Wang, Y., An, J.-Y., Peng, K.-L., & Wang, H. X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963255 · Cited by 3
Chronic Heart Failure: A Pharmacologic Review
Salama, S., Choudhury, A., & Kane, S. P. (2022) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000883 · Cited by 3
Hesse, K. (2022) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2022.100218 · Cited by 6
Negi, P. C., Gupta, A., Thakur, P., Asotra, S., Ganju, N., Marwah, R., Sharma, R., & Kandoria, A. K. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.02.003 · Cited by 3
Shiba, M., Kato, T., Morimoto, T., Yaku, H., Inuzuka, Y., Tamaki, Y., Ozasa, N., SEKO, Y., Yamamoto, E., Yoshikawa, Y., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.023 · Cited by 3
Belenkov, Y. N., Arutyunov, G. P., Mareev, V. Y., Koziolova, N. A., Sitnikova, M. Y., Ageev, F. T., Gilyarevsky, S. R., Chesnikova, A. I., Yаkushin, S. S., Перепеч, Н. Б., et al. (2023) · Kardiologiia · doi:10.18087/cardio.2023.4.n2403 · Cited by 3
Zhang, E., Chen, C., Wang, Y., Weng, Q., Xu, R.-A., & Lin, J. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673258387230921090445 · Cited by 3
Chronic heart failure with reduced EF: A decade of major pharmacological innovations
Trochu, J. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104219 · Cited by 4
Yin, Q., Zheng, X., Song, Y., Wu, L., Li, L., Tong, R., Han, L., & Bian, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1272073 · Cited by 8
Towards etiological treatments in cardiomyopathies
Lairez, O., Fournier, P., Itier, R., Bachelet, B., Huart, A., & Cariou, E. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104223 · Cited by 3
Sun, J., Xie, Z., Ye, M., He, X., Dong, Y., Liu, C., & Zhu, W. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14689 · Cited by 2
“11 As one of the strongest predictors of adverse events in HFrEF, NT-proBNP has been implicated in several risk scores during recent years and performed well in the PREDICT-HF and EMPEROR-Reduced risk scores.”
Chiu, L., Agrawal, V., Armstrong, D., Brittain, E. L., Collins, S., Hemnes, A. R., Hill, J. A., Lindenfeld, J. M., Shah, S. J., Stevenson, L. W., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031796 · Cited by 4
Wang, L., Huo, X., Sun, H., Liu, F., Huang, R., & Zhao, Q. M. (2024) · BMC Public Health · doi:10.1186/s12889-024-18778-2 · Cited by 3
“[9].”
BackgroundMethodInfluentialWang, Y., Zhao, M., Liu, X., Xu, B., Reddy, G. R., Jovanović, A., Wang, Q., Zhu, C., Xu, H., Bayne, E. F., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.03.007 · Cited by 3
How to Change the Medical History of Patients with Heart Failure and Recurrent Hospitalizations?
Andrade, F. A., Monferdini, L., & Vieira, J. L. (2023) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20230092 · Cited by 3
Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic
Liu, X., Benda, N., Mittmann, C., & Koch, A. (2024) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2024.2395404 · Cited by 3
“…Gill 1982) using robust standard errors to account for within-subject correlation, has recently been used as the primary or secondary analysis of recurrent event endpoints in several CHF trials (McMurray et al. 2019; Solomon et al. 2019; Armstrong et al. 2020; Bhatt et al. 2021; Kalra et al. 2022).”
Contemporary clinical role of echocardiography in patients with advanced heart failure
Nuzzi, V., Manca, P., Mulè, M., Leone, S., Fazzini, L., Cipriani, M., & Faletra, F. F. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10434-6 · Cited by 3
“…(HFrEF) on optimal medical therapy: vericiguat, a soluble guanylate cyclase stimulator that increases nitric oxide availability, and omecamtiv mecarbil, a cardiac myosin activator that enhances systolic function which is still under review at the European Medicines Agency for approval [27, 34].”
Pharmacological management of heart failure: a patient-centred approach
Fibbi, G., Sato, R., Vatic, M., Genreith, F. P., & von Haehling, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418414 · Cited by 6
“In a subsequent phase III study, VICTORIA, vericiguat reduced the incidence of CV death or hospitalization in patients with a recent event of worsening HFrEF who were already on GDMT [97].”
Xu, Z., Yang, J., Hu, Y., Wan, Q., Wang, X., Lu, C. Y., & Liu, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119229 · Cited by 4
Transparency in Science Reporting: A Call to Researchers and Publishers
Sturmberg, J. P., & Kühlein, T. (2025) · Cureus · doi:10.7759/cureus.79493 · Cited by 3
Dewan, P., Jhund, P. S., & McMurray, J. J. V. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1833 · Cited by 3
Notch–Rho–cGMP interaction: common point of convergence in microvascular aging-related disease
Roks, A. J. M., Cheng, C., & Shanahan, C. M. (2021) · Clinical Science · doi:10.1042/cs20210288 · Cited by 3
Crocetto, F., Cuomo, V., Santoro, C., Fiorillo, L., Barone, B., Arcaniolo, D., Fedele, T., Imbimbo, C., & Esposito, R. (2022) · Applied Sciences · doi:10.3390/app12115629 · Cited by 3
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.